FOR IMMEDIATE RELEASE

SAGE LAUNCHES NEW MEDICAL JOURNAL SERIES

Los Angeles, London, New Delhi, and Singapore (September 6, 2007) – SAGE, the world’s fifth largest journals publisher, is delighted to announce the launch of a new journals series dedicated to the latest therapies for major world-wide diseases.

The series, encompassing the highest quality peer-reviewed scholarly content, will focus on ground-breaking studies of diseases and emerging pharmacology and medicine. The first journal in the series, Therapeutic Advances in Cardiovascular Disease, was launched on September 2nd at the European Society of Cardiology Annual Congress in Vienna, Austria. The first issue is available online at http://tac.sagepub.com. The second journal, Therapeutic Advances in Respiratory Disease will follow on September 15th at the European Respiratory Society Annual Congress in Stockholm, Sweden. The first issue is also now available online at http://tar.sagepub.com.

“Launching a new journal in an already crowded field is a daunting task,” commented Editor-in-Chief of Therapeutic Advances in Cardiovascular Disease, Carlos M. Ferrario, of North Carolina’s Wake Forest University School of Medicine. “But there is a need for a timely journal that analyzes new therapies for cardiovascular disease. Our first issue (September) addresses cardio-metabolic syndrome and its possible therapies.”

“There is also a real need for a journal to serve the pulmonary research community” agreed Editor-in-Chief of the second journal, Mario Cazzola, of the University of Rome’Tor Vergata’ in Italy. “I’m delighted to launch Therapeutic Advances in Respiratory Disease, not to compete with existing journals, but to complement them. It can be difficult to get smaller studies published in the larger journals, despite the significance of the research, especially for authors whose first language is not English. With SAGE’s first-class production and editing facilities, this will be a platform for all significant research and debate in respiratory pharmacology.”

“We’re very excited by the launch of the Therapeutic Advances journals,” added Ziyad Marar, SAGE Deputy Managing Director and Publishing Director. “Our investment in the series reflects SAGE’s continued commitment to our STM publishing program, complementing our established reputation as the market leader in the social sciences.”

Published bi-monthly starting with Volume 2 in February 2008, the journals are aimed at clinicians and researchers in the fields of cardiovascular and respiratory diseases and will be a forum for all views in these disciplines.

Free online trials to Volume 1 of both journals are available until December 31, 2007. To register for the Therapeutic Advances in Cardiovascular Disease trial, go to https://online.sagepub.com/cgi/register?registration=TAK. To register for the Therapeutic Advances in Respiratory Disease trial, go to https://online.sagepub.com/cgi/register?registration=tar.

Future launches in the series include Therapeutic Advances in Urology & Nephrology, Gastroenterology & Hepatology, Neurological Disorders, and others.
About SAGE
SAGE is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students spanning a wide range of subject areas including business, humanities, social sciences, and science, technology and medicine. A privately owned corporation, SAGE has principal offices in Los Angeles, London, New Delhi, and Singapore. www.sagepublications.com